H with hypertension. The term aTRH, rather than TRH, is used in many epidemiologic studies because comprehensive workups are not conducted and individuals with pseudoresistance (eg, inadequate regimens, doses, medication combinations) cannot be identified and excluded. 4, 5 Despite the recognition of aTRH as a clinical problem, few data are available on the association between aTRH and cardiovascular disease (CVD) outcomes. The high prevalence of aTRH underscores the need to determine its prognostic significance. Therefore, the goal of the current study was to determine the association between aTRH and the incidence of CHD, stroke, all-cause mortality, HF, peripheral arterial disease (PAD), and ESRD. In addition, 2 composite end points of combined CHD and combined CVD were evaluated. To do so, we analyzed data from the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Methods
The design, rationale, baseline characteristics, and main results of ALLHAT have been described in detail previously. [6] [7] [8] [9] [10] In brief, ALLHAT was a randomized controlled trial sponsored by the National Heart, Lung, and Blood Institute of the US National Institutes of Health. It was designed to determine whether treatment with a calcium channel blocker (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), or an α-blocker (doxazosin) lowers the incidence of fatal CHD or nonfatal myocardial infarction (MI), when compared with treatment with a thiazide-type diuretic (chlorthalidone). A total of 42 418 study participants were recruited at 623 clinical sites across the United States, Canada, Puerto Rico, and the US Virgin Islands between February 1994 and January 1998. The doxazosin treatment arm was discontinued in 2000 because of little chance of finding a CHD benefit compared with the chlorthalidone arm along with an excess of CVD events. 7 The main results comparing patients randomized to chlorthalidone, amlodipine, and lisinopril were published in December 2002. 8 All participants provided written informed consent. Institutional review board approval was received for the conduct of ALLHAT and secondary analyses of ALLHAT data.
We defined aTRH at the year 2 study visit. This visit was chosen to allow adequate time for titration of medications and to identify participants with aTRH while maintaining the maximum possible follow-up for outcomes. Because participants randomized to doxazosin had limited follow-up beyond the 2-year study visit, we excluded them from the current analyses. After this exclusion, ALLHAT participants randomized to chlorthalidone, amlodipine, or lisinopril (n=33 357) at baseline formed the base population for the current analyses ( Figure 1 ). 6 We excluded participants with any of the outcomes (defined below) during the study before the year 2 follow-up visit (n=3465) and participants who did not attend (n=5127), have BP measurements available (n=2452), or were missing medication information (n=1) from the year 2 follow-up visit. A 6-month window around the year 2 follow-up visit was allowed for visits to be used to define aTRH. In addition, 7628 participants whose BP was above goal on <3 classes of antihypertensive medications were excluded because we were unable to determine whether they had aTRH or not. After these exclusions, 14 864 participants were available for the current analyses.
BP Measurements and Titration of Medications
BP was measured 2 times by trained observers following standardized techniques. The BP measurements were separated by ≥30 seconds. For the current analysis, BP measurements were calculated as the average of the 2 readings at the study visit occurring 2 years after ALLHAT randomization. The goal BP for participants in ALLHAT was a systolic BP (SBP) <140 mm Hg and a diastolic BP (DBP) <90 mm Hg. The randomization antihypertensive medication class (step 1 therapy) included 12.5 to 25 mg/d for chlorthalidone, 2.5 to 10 mg/d for amlodipine, and 10 to 40 mg/d for lisinopril. If participants did not achieve the BP goal while taking the maximum tolerated dosage of the step 1 medication, a step 2 medication (atenolol, reserpine, or clonidine based on the investigator's choice) was added and increased to the maximal tolerated doses until goal BP was reached. If goal BP was still not achieved, hydralazine could be added as a step 3 agent. Nonstudy open-label drugs could also be added to or substituted for step 2 or 3 medications to improve tolerance or achieve goal BP. After initial monthly titration visits, participants were seen every 3 months during the first year of follow-up and every 4 months thereafter. Medication doses were increased or additional medications were added during follow-up if BP was not at goal. Per national guidelines, lifestyle modification approaches to treat hypertension were recommended to all ALLHAT participants. 11 At the year 2 study visit, participants taking ≥3 classes of antihypertensive medication with BP not at goal (SBP ≥140 mm Hg and DBP ≥90 mm Hg), or those taking 3 Because of the randomization assignment and treatment protocol in ALLHAT, for our primary analyses, inclusion of a diuretic as part of participants' regimen was not required to meet the definition of aTRH.
Covariate Information
Data from the baseline ALLHAT study visit included age, sex, race, ethnicity, region of residence, practice setting (eg, academic, health maintenance organization, etc), education, smoking status, use of antihypertensive medication before enrollment in ALLHAT, evidence of CHD, history of MI or stroke, height, and weight, left ventricular hypertrophy by electrocardiography or echocardiography, or history of type 2 diabetes mellitus (DM). Using blood collected during the study visit, total, high-density lipoprotein, and low-density lipoprotein cholesterol and serum creatinine were measured at the ALLHAT study laboratory. Estimated glomerular filtration rate was calculated using the Modification of Diet in Renal Disease equation.
12

Outcomes
Eight outcomes were studied in this analysis: (1) CHD, (2) stroke, (3) all-cause mortality, (4) combined CHD, (5) combined CVD, (6) HF, (7) PAD, and (8) ESRD. These comprise the primary outcome in ALLHAT and 4 prespecified secondary outcomes and their components. CHD was defined as fatal CHD or nonfatal MI combined, and combined CHD was defined as fatal CHD or nonfatal MI, coronary revascularization, or hospitalized angina. Additionally, combined CVD was defined as combined CHD, stroke, other treated angina, HF (fatal, hospitalized, or treated nonhospitalized), or PAD. ESRD was defined as kidney disease death, renal transplantation, or start of longterm renal dialysis. PAD was defined as occurring for patients with an outpatient or hospitalized treatment, eg, revascularization procedure of a lower extremity. Study outcomes were assessed at follow-up visits and reported to the clinical trials center. Details of the event ascertainment process are provided elsewhere. 6, 8 Participants were followed from the date of their year 2 study visit (ie, when aTRH status was determined) to the date of each outcome, their date of death, or end of active follow-up (October 1, 2001, through March 31, 2002).
Statistical Methods
Characteristics of ALLHAT participants included in this analysis were calculated by aTRH status with the statistical significance of differences determined using t tests or χ 2 tests as appropriate. The cumulative incidence of each outcome was determined using the Kaplan-Meier method. Next, hazard ratios (HRs) for each outcome comparing participants with versus without aTRH were calculated using Cox proportional hazards regression models. HRs were calculated without adjustment and after 3 levels of adjustment. HRs were adjusted initially for age, sex, race/ethnicity, and region of residence. The subsequent level of adjustment also included practice setting, education level, smoking status, and body mass index. The Cumulative incidence for coronary heart disease, stroke, all-cause mortality, heart failure, combined coronary heart disease, combined cardiovascular disease, peripheral arterial disease, and end-stage renal disease for individuals with and without apparent treatment-resistant hypertension (aTRH). Combined coronary heart disease: fatal coronary heart disease or nonfatal myocardial infarction, coronary revascularization, or hospitalized angina. Combined cardiovascular disease: combined coronary heart disease, stroke, other treated angina, heart failure (fatal, hospitalized, or treated nonhospitalized), or peripheral arterial disease. Goal BP was SBP <140 mm Hg and DBP <90 mm Hg. aTRH indicates apparent treatment-resistant hypertension; BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVH, left ventricular hypertrophy; MI, myocardial infarction; and SBP, systolic blood pressure.
*aTRH was defined as having uncontrolled hypertension despite the use of antihypertensive medications from ≥3 classes or the use of ≥4 antihypertensive medication classes to achieve BP control.
†BP at goal while on ≥4 classes on antihypertensive medication. ‡BP not at goal while on ≥3 classes of antihypertensive medication. , DM, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, evidence of CHD, history of MI or stroke, left ventricular hypertrophy, taking antihypertensive medication before randomization, and randomization arm. The full multivariable adjusted HRs were calculated overall and for subgroups defined by age (<65 and ≥65 years of age), race, sex, DM, and evidence of CHD at baseline. These represent a priori and post hoc subgroups reported previously in ALLHAT. 8 The statistical significance of differences in the HR across subgroups was calculated in models including the full population and multiplicative interaction terms (eg, sex×aTRH). A sensitivity analysis was conducted by calculating the HRs for outcomes associated with aTRH restricted to participants randomized to chlorthalidone.
Next, we conducted exploratory analyses to evaluate whether the association between aTRH and outcomes could be explained by differences in SBP and DBP. First, incidence rates for each outcome were calculated for participants with aTRH whose BP was or was not at goal. The HRs for each outcome comparing individuals with aTRH and BP not at goal to those without aTRH were calculated. Because of the low number of participants with aTRH and BP at goal (n=178), we did not calculate full multivariable adjusted HR for this group versus no aTRH. Second, we calculated the HRs for each outcome comparing participants with versus without aTRH including full multivariable adjustment, as described above, plus SBP and DBP levels from the ALLHAT baseline visit and the 2-year follow-up visit (ie, when aTRH was ascertained).
Results
Characteristics of included and excluded participants are provided in Table S1 in the online-only Data Supplement. Among the 14 684 ALLHAT participants included, 12.7% had aTRH. The mean age (SD) of participants with (n=1870) and without aTRH (n=12 814) was 66.6 (7.5) and 66.3 (7.4) years, respectively (Table 1 , left panel). Compared with their counterparts without aTRH, participants with aTRH were more likely to be black, live in the south of the United States, be recruited into ALLHAT from a community health center or Veterans Affair Medical Center, have less than a high school education, and never smoked. They also had a higher body mass index, lower estimated glomerular filtration rate, were more likely to have DM or left ventricular hypertrophy, and been on antihypertensive medication before ALLHAT randomization. Participants meeting criteria for aTRH after 2 years of follow-up were more likely than those without aTRH to have been randomized to lisinopril and less likely to have been randomized to chlorthalidone. The distribution of antihypertensive medication classes being taken at the year 2 ALLHAT study visit by aTRH status is provided in Table S2 .
The incidence of each outcome was higher among individuals with versus without aTRH (Figure 2 ). In unadjusted models and after adjustment for age, sex, race/ethnicity, and region of residence, aTRH remained associated with an increased HR for each outcome ( Table 2 ). The HR remained similar after further adjustment for practice setting, education, smoking status, and body mass index. After full multivariable adjustment, the HR for each outcome except PAD remained statistically significant (HR for PAD, 1.23; 95% confidence interval [CI], 0.85-1.79). Although attenuated, the full multivariable adjusted HR for ESRD associated with aTRH remained statistically significant (HR, 1.95; 95% CI, 1.11-3.41). With a few exceptions, aTRH remained associated with outcomes in subgroup analysis (Figure 3 ). Among participants randomized to chlorthalidone, aTRH was associated with an increased risk for combined CHD, combined CVD, HF, PAD, and ESRD after multivariable adjustment (Table S3 ). The HR for CHD comparing participants with versus without aTRH was 1.32 (95% CI, 0.96-1.83).
Characteristics of participants with aTRH with and without BP at goal are provided in the right panel of Table 1 with the antihypertensive medications being taken by these 2 groups provided in the right panel of Table S2 . Compared with individuals without aTRH, the incidence rates of CHD, combined CHD, combined CVD, HF, and ESRD were higher among individuals who had aTRH with BP at goal (Table 3) . Also, participants with aTRH and BP not at goal had a higher incidence rate of each outcome when compared with individuals without aTRH. After full multivariable adjustment and compared with individuals without aTRH, those with aTRH and whose BP was not at goal had an increased HR for each outcome except PAD (Table 4) . In a full multivariable adjusted model that also included SBP and DBP from the ALLHAT baseline visit and the year 2 study visit, the HRs comparing participants with versus without aTRH were 1.35 (95% CI, 1.03-1.78) for CHD, 1.49 (95% CI, 1.00-2.21) for stroke, 1.30 (95% CI, 1.05-1.61) for all-cause mortality, 1.60 (95% CI, 1.18-2.16) for HF, 1.04 (95% CI, 0.63-1.71) for PAD, and 1.12 (95% CI, 0.48-2.62) for ESRD. Additionally, the HR for combined CHD and combined CVD after additional adjustment for SBP and DBP were 1.22 (95% CI, 0.99-1.50) and 1.30 (95% CI, 1.10-1.53), respectively.
Discussion
In this secondary analysis of a large randomized trial of participants with hypertension, aTRH was associated with an increased risk for CHD, stroke, all-cause mortality, CVD, HF, and ESRD. These associations were independent of many potential confounding factors including demographics, smoking status, estimated glomerular filtration rate, DM, and left ventricular hypertrophy. Additionally, the increased risk for these outcomes was present in subgroups defined by demographics and history of DM and CHD. The vast majority of individuals with aTRH in the current analysis had uncontrolled BP highlighting the importance of optimizing antihypertensive therapy to control BP and reduce the incidence of adverse CVD and renal outcomes. In addition, this higher risk may also suggest that other interventions to lower CVD risk, such as lifestyle changes, lipid-lowering medications, or aspirin, may also be a high priority in patients with aTRH.
At least 3 prior studies have reported an association between aTRH and CVD. In the Cardiovascular Disease Research Network, compared with people with hypertension and no aTRH, aTRH was associated with a multivariable adjusted HR of 1.47 (95% CI, 1.33-1.62) for the composite outcome of death, stroke, MI, chronic kidney disease or HF, which is similar to the HR for combined CVD in our report. 13 The adjusted HR for each separate outcome was not reported. The association between aTRH was also investigated in a population at high risk for CVD in the Reduction of Atherothrombosis for Continued Health (REACH) registry.
14 This registry included patients with ≥3 risk factors for atherosclerosis of whom 80% had a history of CVD at baseline. In the REACH registry, aTRH was defined as a SBP/DBP ≥140/90 mm Hg (≥130/80 mm Hg if DM or chronic kidney disease was present) with the concomitant use of ≥3 antihypertensive medications, including a diuretic or use of ≥4 antihypertensive medications, including a diuretic, regardless of whether BP was at goal. In the REACH registry, when compared with patients with hypertension but who did not meet the study's definition for aTRH, aTRH was associated with an increased risk of the pooled outcome of CVD mortality, MI, or stroke (HR, 1.16; 95% CI, 1.08-1.24). Additionally, aTRH was associated with an increased risk for all-cause and CVD mortality, nonfatal MI, and HF hospitalization. In contrast, in the REACH registry, no association was present between aTRH and stroke. An association between aTRH and cardiovascular events was also present in the Treating to New Targets trial, a population with established coronary artery disease. 15 The data from ALLHAT extend the results from previous studies in several important ways. First, we documented aTRH to be associated with an increased risk of outcomes including ESRD. Second, following the protocol of ALLHAT, patients were titrated to the maximum dose of the step 1 drug if BP was not at goal before an additional drug was added. Prior studies did not incorporate an active process for adjusting medications in an attempt to achieve BP control. Third, ALLHAT included a large number of blacks, a population with a high burden of Incidence rate* (95% CI) 1.6 (1.2-2.0) 5.1 (3.6-7.4) 4.0 (1.0-15.9) 5.3 (3.6-7.7)
CHD outcome: fatal CHD or nonfatal myocardial infarction combined. Combined CHD: fatal CHD or nonfatal myocardial infarction coronary, revascularization, or hospitalized angina. Combined CVD: combined CHD, stroke, other treated angina, heart failure (fatal, hospitalized, or treated nonhospitalized), or peripheral arterial disease. Blood pressure at goal while on ≥4 classes on antihypertensive medication. Blood pressure not at goal while on ≥3 classes of antihypertensive medication. aTRH indicates apparent treatment-resistant hypertension; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; ESRD, end-stage renal disease; and LVH, left ventricular hypertrophy.
*Incidence rates are per 1000 person-years.
by guest on April 20, 2017 http://hyper.ahajournals.org/ Downloaded from hypertension and for whom BP is a particularly potent CVD and renal disease risk factor. For example, in prior studies, the association of higher SBP with stroke and ESRD incidence has been reported to be stronger for blacks compared with whites. 16, 17 In the current study, aTRH was associated with each outcome to a similar extent in blacks and whites. Nonetheless, the prevention and treatment of aTRH remains especially important in blacks given its substantially higher prevalence.
ALLHAT was designed to test the benefits of amlodipine, lisinopril, and doxazosin versus chlorthalidone on CVD and renal outcomes. Management of BP in ALLHAT followed a protocol for dose titration and the addition of medications for participants with BP not at goal. Importantly, the second and third step agents to be prescribed for participants with BP not at goal in ALLHAT were atenolol, reserpine, and clonidine (step 2) and hydralazine (step 3). Although an aldosterone receptor antagonist could be prescribed as an open-label step 3 agent, it was not commonly used. Prior studies have highlighted the ability to achieve substantial reductions in BP with the use of aldosterone receptor antagonists in individuals with hard to control BP. 18, 19 Whether these agents reduce CVD and renal disease risk among patients with aTRH was beyond the scope of the current study but should be investigated in the future.
The vast majority of ALLHAT participants with aTRH had BP above goal (ie, SBP ≥140 or a DBP ≥90 mm Hg). It is well known that higher BP levels are associated with an increased risk for the adverse CVD and renal outcomes we investigated. 2, [20] [21] [22] Fewer data are available on the association between BP and CVD and renal outcomes in the context of aTRH. In the current study, the crude incidence rates of CHD, combined CHD, combined CVD, HF, and ESRD were each higher among the subset of individuals with aTRH and BP at goal (ie, SBP <140 or a DBP <90 mm Hg) versus no aTRH. Notably, with the exception of PAD and ESRD, aTRH remained associated with outcomes after adjustment for SBP and DBP in an exploratory analysis. We think this result should be interpreted with caution. Given the large difference in SBP and DBP between those with and without aTRH, residual confounding may have remained present even after statistical adjustment. This analysis may indicate the presence of vascular damage, perhaps attributable to long-standing uncontrolled BP, among patients with aTRH. Although beyond the scope of the current analysis, further research is needed to determine whether the increased CVD and ESRD risk associated with aTRH can be eliminated through aggressive BP reduction.
There are several known and potential limitations of the current analysis. ALLHAT participants were randomized to their initial antihypertensive drug class, and the step 2 therapy did not include the other randomization drug classes, as would typically be the case in current practice. For this reason, we did not require the use of a diuretic for the definition of aTRH for our primary analyses. aTRH was associated with increased risk for combined CHD, combined CVD, HF, PAD, and ESRD when we restricted our analyses to participants randomized to chlorthalidone. The lack of associations between aTRH and stroke and all-cause mortality in this sensitivity analysis may be the result of a low number of cases among ALLHAT participants randomized to chlorthalidone. Caution should be taken when interpreting the prevalence of aTRH in ALLHAT because participants who were taking >2 BP medications and those with SBP >180 mm Hg or DBP >110 mm Hg on 2 separate occasions in the screening or stepdown process were excluded from participation in the study. Average followup for the current analyses was only 4.9 years. The impact of long-standing aTRH, and aTRH over longer follow-up periods, on CVD and renal outcomes should be investigated in future ), diabetes mellitus, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, evidence of CHD, history of myocardial infarction or stroke, left ventricular hypertrophy, taking antihypertensive medications before randomization, and randomization arm.
§CHD outcome: fatal CHD or nonfatal myocardial infarction combined. ║Combined CHD: fatal CHD or nonfatal myocardial infarction, coronary revascularization, or hospitalized angina. ¶Combined CVD: combined CHD, stroke, other treated angina, heart failure (fatal, hospitalized, or treated nonhospitalized), or peripheral arterial disease.
by guest on April 20, 2017 http://hyper.ahajournals.org/ Downloaded from studies. However, because ALLHAT excluded severe and resistant hypertension at entry, it is likely that the risk for the aTRH cohort would have been even higher if they were included. Despite these limitations, there are a number of strengths associated with using ALLHAT to study aTRH including a large sample size and enrollment of a diverse population including a large number of blacks. Additional strengths include a protocol for the titration of antihypertensive drugs and standardized measurement of BP and the availability of 8 adjudicated outcomes. The strong and consistent association of aTRH with 7 of the 8 outcomes is compelling, especially because the relative strength of associations across outcomes is consistent with the usual relationships seen between BP and outcomes.
The findings from this analysis have important clinical implications. The high morbidity associated with aTRH highlights the importance of identification and appropriate management of patients with aTRH. Recognition of aTRH should prompt a systematic evaluation for the underlying factors, including incomplete adherence that may be contributing to resistance to treatment. Reinforcement of lifestyle measures along with newer pharmacologic approaches to treat aTRH such as aldosterone antagonists can often result in improved BP control. Attention to other interventions to reduce CVD risk, such as lifestyle measures, lipid lowering, or aspirin, may also be beneficial in this population. Finally, the development of new investigational interventional therapies may have an important role in resistant hypertension. 23, 24 Whether the interventions will be proven to be safe and effective and will reduce the high risk of CVD and other events associated with aTRH remains to be seen.
Perspectives
The current analysis demonstrates a strong association between aTRH with CHD, stroke, all-cause mortality, composite CHD and CVD outcomes, HF, and ESRD. Along with previous data showing that aTRH affects a substantial proportion of US adults with hypertension, 4 the current study underscores the importance of improving treatment for patients with hard to control BP. Future studies are needed to identify approaches for preventing aTRH as well as reducing the risk for CVD and renal outcomes once patients develop aTRH.
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